Search

everythinglearnresearchcommunity

for

Search:↓

A new compound shows promise as a topical treatment for hair loss.

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

The enzyme from human skin can cross-link proteins and needs calcium to work.

PI3K/Akt pathway is crucial for hair growth and regeneration.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Understanding tissue remodeling can help create precise treatments for various organ issues.

CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.

Microglia are essential for zebrafish brain repair by controlling inflammation.

ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.

JAK inhibitors, PRP, and exosomes show promise for hair regrowth in Alopecia Areata.

Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Proteolytic activity in mouse skin changes with hair cycle stages, peaking in early anagen.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.

TGF-β and TNF influence hair follicle cell fate, with TNF being more effective in triggering cell death.

The DMI3 gene is essential for nodule development and symbiosis in certain plants.

PAD type III enzyme is specific to rat skin and hair follicles.

Gab1 protein is crucial for hair growth and stem cell renewal, and Mapk signaling helps maintain these processes.

Early intervention with JAK inhibitors may prevent alopecia areata progression.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Krt6a-Cre transgenic mice help study gene effects on hair follicle development and tumor suppression.

The TGF-β family helps control how cells change and move, affecting skin, hair, and organ development.

Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

A new 3D breast tumor model helps test drug effects more accurately than traditional methods.

Oral JAK inhibitors help regrow hair in alopecia patients.

A new protein was made to detect specific skin cell growth receptors and worked in normal skin but not in skin cancer cells.

Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.

Tsc2-deficient stem cells can help understand and treat TSC-related tumors.